Low-dose colchicine for the prevention of postoperative atrial fibrillation after bypass surgery: Results from the COLPOAF study
Archives of Cardiovascular Diseases · 2026-09
DOI: 10.1016/j.acvd.2026.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Cardiovascular Diseases, 2026-09. Verfasst von Valentin Roger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University of Montpellier 34090 Montpellier, France. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Postoperative atrial fibrillation (POAF) is common after cardiac surgery and is associated with adverse outcomes. Standard-dose colchicine could reduce POAF incidence but is limited by poor tolerability. Low-dose colchicine (0.5mg daily) is recommended for secondary prevention in coronary artery disease with a favourable safety profile. AIMS: To compare the incidence of POAF following coronary artery bypass grafting (CABG) between patients who received low-dose colchicine and those managed with standard care. METHODS: COLPOAF is an observational, retrospective, before-after, single-centre study conducted in a tertiary care hospital in France. A total of 206 patients who underwent CABG between November 2024 and January 2026 (treated with low-dose colchicine) were compared with a historical control group of 244 patients operated on between May 2023 and July 2024 (without colchicine). The primary efficacy endpoint was the incidence of POAF between postoperative day 3 and hospital discharge. RESULTS: Baseline characteristics were well balanced between the two groups. POAF occurred in 23 patients (11.2%) in the colchicine group and 29 patients (11.9%) in the standard care group, with a hazard ratio of 0.92 (95% confidence interval 0.53-1.59; P=0.76). Gastrointestinal adverse events were more frequent with colchicine (7.8 vs. 2.5%), leading to drug discontinuation in 12 patients (5.8%). No major adverse events were attributed to colchicine. C-reactive protein levels were significantly lower in the colchicine group. CONCLUSION: Low-dose colchicine was not significantly associated with a reduction in POAF after CABG. The overall safety profile remained acceptable with no severe treatment-related complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, University of Montpellier 34090 Montpellier, France.
- Cardiac Surgery Department, University of Montpellier, 34090 Montpellier, France.
- Clinical Research and Epidemiology Unit, CHU of Montpellier, Montpellier University, 34090 Montpellier, France.
- PhyMedExp, Cardiology Department, Inserm U1046, CNRS UMR, 9214; INI-CRT, University of Montpellier, 371, avenue du doyen-Gaston-Giraud, 34000 Montpellier, France. Electronic address: f-roubille@chu-montpellier.fr.
Zitieren
APA
Roger, V., Martinez, D., Gandet, T., Demaria, R., Rouviere, P., Souidene, S., Nigolean, A., Brunet, M. C., Leclercq, F., Moulis, L., & Roubille, F. (2026). Low-dose colchicine for the prevention of postoperative atrial fibrillation after bypass surgery: Results from the COLPOAF study. Archives of Cardiovascular Diseases. https://doi.org/10.1016/j.acvd.2026.07.008
Vancouver
Roger V, Martinez D, Gandet T, Demaria R, Rouviere P, Souidene S, et al. Low-dose colchicine for the prevention of postoperative atrial fibrillation after bypass surgery: Results from the COLPOAF study. Archives of Cardiovascular Diseases. 2026. doi:10.1016/j.acvd.2026.07.008
BibTeX
@article{Roger2026,
author = {Roger, Valentin and Martinez, David and Gandet, Thomas and Demaria, Roland and Rouviere, Philippe and Souidene, Sofiene and Nigolean, Alexandru and Brunet, Marie Clothilde and Leclercq, Florence and Moulis, Lionel and Roubille, François},
title = {Low-dose colchicine for the prevention of postoperative atrial fibrillation after bypass surgery: Results from the COLPOAF study},
journal = {Archives of Cardiovascular Diseases},
year = {2026},
doi = {10.1016/j.acvd.2026.07.008}
}
EUVIMED